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Mouse modelHypertrophic cardiomyopathy (HCM) is frequently caused by mutations in MYBPC3 encoding cardiac myosin-
binding protein C (cMyBP-C). Themechanisms leading fromgenemutations to theHCMphenotype remain incom-
pletely understood, partially because current mouse models of HCM do not faithfully reﬂect the human situation
and early hypertrophy confounds the interpretation of functional alterations. The goal of this studywas to evaluate
whether myoﬁlament Ca2+ sensitization and diastolic dysfunction are associated or precede the development of
left ventricular hypertrophy (LVH) in HCM. We evaluated the function of skinned and intact cardiac myocytes,
as well as the intact heart in a recently developedMybpc3-targeted knock-in mouse model carrying a point muta-
tion frequently associated with HCM. Compared to wild-type, 10-week old homozygous knock-in mice exhibited
i) higher myoﬁlament Ca2+ sensitivity in skinned ventricular trabeculae, ii) lower diastolic sarcomere length, and
faster Ca2+ transient decay in intactmyocytes, and iii) LVH, reduced fractional shortening, lower E/A and E′/A′, and
higher E/E′ ratios by echocardiography and Doppler analysis, suggesting systolic and diastolic dysfunction. In con-
trast, heterozygous knock-inmice,whichmimic the humanHCMsituation, did not exhibit LVHor systolic dysfunc-
tion, but exhibited higher myoﬁlament Ca2+ sensitivity, faster Ca2+ transient decay, and diastolic dysfunction.
These data demonstrate thatmyoﬁlament Ca2+ sensitization and diastolic dysfunction are early phenotypic conse-
quences ofMybpc3mutations independent of LVH. The accelerated Ca2+ transients point to compensatory mech-
anisms directed towards normalization of relaxation. We propose that HCM is a model for diastolic heart failure
and this mouse model could be valuable in studying mechanisms and treatment modalities.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Hypertrophic cardiomyopathy (HCM) is themost commonheritable
cardiac disorder characterized by left ventricular hypertrophy (LVH),
diastolic dysfunction and interstitial ﬁbrosis [1–3]. Affected individualstein C; cTnI, cardiac troponin I;
y; Het, heterozygous Mybpc3-
d knock-in mice; KO, homozy-
ular hypertrophy; max F, max-
yosin-binding protein C gene;
e; NCX, Na+/Ca2+ exchanger;
% of maximal activation; PKA,
an; SERCA2, SR-Ca2+ ATPase;
l Pharmacology and Toxicology,
istraße 52, D-20246 Hamburg,
925.
-NC-ND license. can be asymptomatic for decades or develop breathlessness, chest
pain, congestive heart failure, or sudden death. Over the past 20 years,
>500 different mutations in at least 19 different genes have been
shown to cause HCM (for reviews see [4–7]). Most encode proteins of
the sarcomere. Among known HCM mutations, those affecting
MYBPC3 encoding cardiac myosin binding protein C (cMyBP-C) are
one of the most frequent (for reviews, see [8,9]). cMyBP-C is located
in the C-zones of the A-band of the sarcomere, and modulates actin–
myosin interaction via phosphorylation by different kinases (for re-
views, see [9–11]). cMyBP-C is hypophosphorylated in HCM and in
human and experimental heart failure [12–14], suggesting a role in di-
astolic dysfunction under these conditions.
Although human studies have been particularly informative in iden-
tifying disease-causing genes, they are limited because of the small
number of individuals carrying the same mutation and the difﬁculty
in obtaining myocardial tissue from patients. Accordingly, much of our
current knowledge about the molecular pathogenesis has been derived
from mouse models of HCM.
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model, carrying a point mutation [15], which frequently causes HCM
and is associated with a severe phenotype and poor prognosis in
humans [16,17]. The genetic architecture of this model closely reca-
pitulates the situation in patients. Whereas homozygous (KI) knock-
in mice developed LVH, reduced fractional shortening and interstitial
ﬁbrosis, heterozygous (Het) knock-in mice were apparently normal
[15]. However, both Het and KI mice are susceptible to stress, which
presented with impairment of the ubiquitin–proteasome system
[18,19]. The lack of LVH in Het appears to be in line with a common
limitation of existing HCM mouse models [11,15,20–23], which de-
velop a disease only in the homozygous state whereas patients with
HCM are usually heterozygous for a mutation (rare homozygous
cases developed DCM and early death) [16]. However, the absence
of LVH in young Het mice mimics the situation in the apparently un-
affected patients carrying a disease mutation [24–26], and gave us the
chance to study early functional alterations that precede LVH. By ex-
tensive phenotypic characterization of Het and KI hearts relative to
wild-type (WT), the data now demonstrate that myoﬁlament Ca2+A
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quences of the Mybpc3 mutation, independent of LVH.
2. Material and methods
2.1. Animals
The investigation conforms to the guide for the care and use of lab-
oratory animals published by the NIH (Publication No. 85–23, revised
1985). The Mybpc3-targeted Het and KI mice were generated by tar-
geted insertion of a G>A transition on the last nucleotide of exon 6
(Fig. 1) [15], and were maintained on the Black Swiss background.
2.2. Assessment of myoﬁlament function in skinned mouse ventricular
trabeculae
Mechanical function of skinned mouse cardiac trabeculae isolated
from 7–8-week-old mice was assessed at 18 °C, using equipment and
protocols similar to those described in detail previously [27]. Skinned6 7 8 9
6 7 8 9
G>A
5 7 8 9
PTC
5 6 7 8 9
5 7 8 9
C0 C1
C0 C1 C2PPP C3 C4 C5 C6 C7 C8 C9 C10
C0 C1 --P C2 C3 C4 C5 C6 C7 C8 C9 C10
I
5 6 7 8 9
G>A
5 7 8 9
PTC
5 6 7 8 9
5 7 8 9
C0 C1
C0 C1 C2PPP C3 C4 C5 C6 C7 C8 C9 C10%
C0 C1 --P C2 C3 C4 C5 C6 C7 C8 C9 C10
5 6 7 8 9
G>A
G>A
es, mRNAs and proteins in heterozygous Mybpc3-targeted knock-in (Het) mice. Het-KI
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nt-2 contains a premature termination codon (PTC) in exon 9 and produces a 32 kDa-
retains parts of intron 8, which restores the reading frame, and produces a 147-kDa
alleles, mRNAs and proteins in homozygous Mybpc3-targeted knock-in (KI) mice. KI
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and ﬁtted to the Hill equation to yield maximal Ca2+-activated force
(max F), the log of [Ca2+] required for 50% of maximal activation
(pCa50), and the Hill coefﬁcient (nH).2.3. Sarcomere shortening and Ca2+ transients in adult mouse ventricular
myocytes
Adult ventricular myocytes were isolated from 13-week-oldmice as
previously described [28]. Sarcomere shortening and Ca2+ transients
were simultaneously assessed upon ﬁeld stimulation (0.25–3 Hz with
4-ms-duration, 10 V) using a video-based sarcomere length (SL) detec-
tion system (IonOptix corporation) at room temperature. Caffeine
(10 mM) was applied to determine sarcoplasmic reticulum (SR) Ca2+
content and the activity of the Na+/Ca2+ exchanger (NCX; [29]).2.4. Echocardiography
Transthoracic echocardiography was performed using the Vevo
2100 System (VisualSonics, Toronto, Canada) in 10-week-old mice
[15]. B-mode recordings were performed using a MS 400 transducer
(18–38 MHz) with a frame rate of 230–400 frames/s to assess left
ventricular (LV) dimensions. Pulsed-wave Doppler echocardiography
was used to measure early (E) and late (A) blood ﬂow velocities through
the mitral valve, and Tissue Doppler imaging to measure early (E′) and
late (A′) velocities of the mitral annulus [30]. All images were recorded
digitally and analysis was performed using the Vevo 2100-software.2.5. Immunoblot analysis
Immunoblot analysis was carried out as previously described
[31,32].2.6. Statistical analysis
Data are expressed as mean±SEM. Comparisons were performed
using Student's t-test, or using one-way or two-way ANOVA followed
by Bonferroni's post-tests. A value of Pb0.05 was considered statisti-
cally signiﬁcant.3. Results
3.1. Higher myoﬁlament Ca2+ sensitivity in Het and KI skinned ventricular
trabeculae
We ﬁrst assessed the force–pCa relationships in skinned ventricu-
lar trabeculae isolated from the 3 groups of mice. Trabeculae were in-
cubated for 30 min with 240 Units of cAMP-dependant protein kinase
A (PKA) to eliminate effects of potential phosphorylation differences,
which could obscure data interpretation. Both Het and KI skinned tra-
beculae exhibited higher myoﬁlament Ca2+ sensitivity than WT
(Figs. 2A and B), whereas the steepness of the force–pCa relationships
and the maximal force (max F) were not affected (Fig. 2B).
To conﬁrm that sarcomeric proteins were phosphorylated to the
same extent in all groups, we performed Western blot analysis of
PKA-treated skinned trabeculae. The level of phosphorylated Ser23/
24-cTnI did not differ between the groups (Fig. 2C). Phosphorylation
of cMyBP-C at the Ser282 site did not differ between Het and WT,
but was markedly lower in KI skinned trabeculae despite the
expected lower level of total cMyBP-C [15]. This likely corresponds
to the fact that b10% of cMyBP-C mutants in KI are mutant-1, which
contains the Ser282 site, and the rest mutant-3, which does not con-
tain this site (Fig. 1) [15].3.2. Blunted negative force–frequency relationship in Het and KI intact
myocytes
We then evaluated sarcomere shortening and Ca2+ transients in
intact cardiac myocytes at different pacing frequencies. As expected
for rodents [33], increasing pacing frequency from 0.25 to 1 Hz de-
creased amplitudes of the twitch and Ca2+ transient in WT myo-
cytes (Figs. 3A and B). Both parameters were lower at 0.25 Hz in
KI, and to a lower extent in Het than in WT myocytes, but remained
stable over the entire frequency range. The lack of the negative
staircase phenomenon suggested abnormal Ca2+ homeostasis in
mutant mice.
3.3. Faster decay of Ca2+ transients in Het and KI intact myocytes
To get a more detailed view of the relation between sarcomere
length and cytosolic [Ca2+] ([Ca]i), we assessed phase-plane dia-
grams as previously described [28]. Results obtained at 2 Hz are
shown (Fig. 4). This analysis shows a shift toward lower diastolic SL
in KI only. The application of 2,3-butanedione monoxime, which dis-
rupts cross-bridge cycling [34] normalized the diastolic SL in KI (Sup-
plemental Table). Furthermore, in both KI and Het, the area of the
loop was larger and the relaxation trajectories were shifted to the
left, i.e. relaxation began at lower [Ca2+]i, supporting increased myo-
ﬁlament Ca2+ sensitivity.
Whereas the kinetics of sarcomere shortening did not differ in the
three groups, Ca2+ transients were shorter in Het and KI myocytes at
2 Hz (Fig. 4B and data not shown). This was also observed at 0.25 Hz
(data not shown). This suggests that the elevatedmyoﬁlament Ca2+ sen-
sitivity is partially compensated by accelerated Ca2+ transient decay, po-
tentially through faster re-uptake of Ca2+ into the SR and/or faster Ca2+
extrusion through NCX. To follow this reasoning, we evaluated SR Ca2+
content and NCX activity by recording caffeine-induced Ca2+ transients
(Fig. 5). The amplitude of caffeine-induced Ca2+ transients did not differ
between the groups (Fig. 5B), suggesting normal SR Ca2+ content. How-
ever, in accordance with faster Ca2+ transients under pacing (Fig. 4),
Ca2+ decay was >2-fold faster in Het and KI than in WT, suggesting
higher NCX activity (Fig. 5C).
3.4. Compensatory molecular changes in Het and KI ventricular tissue
We next analyzed whether the blunted force–frequency relation-
ship and faster Ca2+ transient decay in Het and KI myocytes were as-
sociated with changes in the phosphorylation of myoﬁlament (Fig. 6)
or Ca2+ handling proteins (Fig. 7) in ventricular tissue. Supporting
the data obtained in skinned ventricular myocytes (Fig. 2), the rela-
tive Ser282-phosphorylation level was lower in KI ventricular ex-
tracts (Fig. 6). No changes in Ser282-phosphorylation were
observed in Het. Ser23/24-phosphorylation of cardiac troponin I
(cTnI) also did not differ between the groups (Fig. 6). Levels of SR-
Ca2+-ATPase (SERCA2), total-phospholamban (PLB) and SERCA2/
PLB ratio as well as phosphorylation of PLB (at Ser16 and Thr17;
Fig. 7) also did not differ. Surprisingly, however, the concentrations
of NCX1 at both apparent molecular weights (160 and 120 kDa) and
of the corresponding mRNA were lower in KI and, to a lesser extent
in Het than in WT mice (Fig. 7).
3.5. Diastolic dysfunction in Het and KI mice
The results in skinned ventricular trabeculae and intact myocytes
suggested that the increased Ca2+ sensitivity in Het and KI is partially
compensated by accelerated Ca2+ transients, promoting relaxation. To
evaluate how these alterations translate into whole heart function, we
evaluated cardiac function in 10-week-old WT, Het and KI mice by
echocardiography. The left ventricular mass-to-body-weight ratio was
higher and the fractional area shortening smaller in KI than in WT
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Fig. 2. Ca2+ sensitivity of force development in WT, Het and KI skinned ventricular trabeculae. Trabeculae were incubated for 30 min with 0.1 U/μl PKA. A, The mean force-pCa
curves were obtained at a sarcomere length of 2.2 μm. Force values were normalized to the maximum force, measured at pCa 4.5. B, pCa50, maximal force and nH (11–13 trabeculae
from 4 hearts per group). C, Western blots stained with the indicated antibodies and bars showing the Ser282-/total-cMyBP-C and Ser23/24-/Total-cTnI protein levels. Values are
expressed as mean±SEM, *Pb0.05 and ***Pb0.01, one-way ANOVA plus Bonferroni post-test. Number of samples is indicated in the bars.
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Using conventional pulsed-wave Doppler echocardiography, peak early
(E) and late (A) blood ﬂow velocities through the mitral valve were
measured (Fig. 8 C). From the tissue Doppler imaging measured at the
septal corner of themitral annulus, peak early (E′) and late (A′) diastolic
velocities were measured (Fig. 8D). In WT mice, E/A and E′/A′ ratios
were >1.5 (Fig. 7E). In Het and KI mice, E/A and E′/A′ ratios were
lower that in WT (Fig. 8E). Conversely, E/E′ ratio was higher in Het
and KI mice than in WT (Fig. 8E). These data strongly suggest diastolic
dysfunction in Het and KI mice.4. Discussion
The present study evaluated in heterozygous and homozygous
Mybpc3-targeted knock-in mice whether alterations in the function
of skinned ventricular muscle preparations and intact ventricular
myocytes in vitro as well as the intact heart in vivo precede the devel-
opment of LVH, and may therefore represent primary changes, rather
than secondary responses, in HCM. The major ﬁndings of this study
were as follows. Compared to WT, KI mice exhibited i) higher myoﬁl-
ament Ca2+ sensitivity in skinned trabeculae, ii) lower diastolic SL
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tolic and diastolic dysfunction in vivo. Het mice, whose genotype
closely mimics the situation in human HCM, exhibited higher myoﬁl-
ament Ca2+ sensitivity in skinned trabeculae, faster Ca2+ transient
decay in intact myocytes, and diastolic dysfunction in vivo. These al-
terations were observed in the absence of LVH or systolic dysfunction
in Het mice, providing the ﬁrst evidence in a disease-relevant gene-
targeted mouse model of HCM that myoﬁlament Ca2+ sensitization
and diastolic dysfunction are primary phenotypic consequences of
the Mybpc3 mutation.
The data in homozygous KImice essentially support and extend ear-
lier data in homozygous KO mice, demonstrating higher Ca2+ sensitiv-
ity in skinned myocytes [35], as well as lower diastolic SL and altered
phase-plane diagrams in intact myocytes [28]. The shift to lower SL
aswell as the larger area of the [Ca2+]i-SL phase-plane diagram in KI re-
capitulates the effect of alkalosis or pharmacological Ca2+ sensitizers
[36,37]. This suggests that they are the consequences of a primary in-
crease in myoﬁlament Ca2+ sensitivity. Taken together, the data sup-
port the concept that cMyBP-C normally prevents residual crossbridge
cycling at low cytosolic Ca2+ concentrations in diastole and thereby
promotes diastolic relaxation [28,38]. Lack of cMyBP-C in KO or its
marked reduction in KI [15] makes myoﬁlaments hyperreactive to1.5
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One of the problems of experiments in homozygous KI and KOmice
is the presence of LVH, even in very young animals [15,21,22]. Thus, it is
difﬁcult to deduce whether the observed changes are primary conse-
quences of cMyBP-C deﬁciency and/or secondary to cardiac myocyte
hypertrophy, which is known to be associatedwith contraction slowing
and altered Ca2+ cycling (for review, see [11]). The most interesting
data are therefore the ﬁndings in Het mice. At 10 weeks of age, Het
mice exhibited normal ventricular weight and normal systolic heart
function. Thus, similar to many HCM patients at young age, they
appeared unaffected at ﬁrst sight. However, a more detailed analysis
revealed several abnormalities. (1) Skinned muscles and intact myo-
cytes from Het mice exhibited increased Ca2+ sensitivity. (2) Most im-
portantly, from a clinical point of view, Het mice exhibited diastolic
dysfunction as evidenced by reduced E/A and E′/A′ratios.
In both Het and KI mice, we found evidence for at least one mecha-
nism of compensation. Myocytes from both Het and KI mice exhibited
accelerated Ca2+ transient decay. The exact reason for the increased ve-
locity of Ca2+ removal from the cytosol is unknown, but SERCA2/PLB
protein and phosphorylation levels were shown to be unaffected, mak-
ing enhanced rates of Ca2+ uptake into the SR unlikely. Unaltered SRTime to 90% relengthening
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major other Ca2+ extrusion route is NCX, the ﬁnding of decreased
NCX mRNA and protein levels came as a surprise. In human systolic
heart failure Ca2+ transients are prolonged [39], NCX levels are elevated
[40], and intracellular [Na+] is increased [41]. This is associated and
likely causally related to a reversal of the positive force–frequency rela-
tionship in human heart to a ﬂat or negative one [42]. The changesA
Fig. 6. Determination of sarcomeric protein phosphorylation in ventricular tissue from10-week
ed against total and Ser282-phosphorylated cardiac myosin-binding protein-C (total-cMyBP-C
(total-cTnI and Ser23/14-cTnI), and calsequestrin (CSQ); B) Ser282-/Total cMyBP-C levels an
test. Number of mice is indicated in the bars.observed in Het and KI myocytes point in the opposite direction
(shorter Ca2+ transients, NCXdown, negative force–frequency relation-
ship reversed to a ﬂat one), suggesting that Het and KI myocytes may
have decreased intracellular [Na+], facilitating Ca2+ extrusion via the
NCX. Clearly more work is needed to substantiate this hypothesis.
The present data have implications for the understanding and po-
tentially treatment of diastolic dysfunction in HCM and beyond. First,Ser23/24- / Total-cTnI
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Fig. 7. Determination of Ca2+ handling protein or mRNA levels in ventricular tissue from 10-week-oldWT, Het and KI mice. A) RepresentativeWestern blots stained with antibodies di-
rected against SR-Ca2+-ATPase (SERCA2), total phospholamban (Total-PLB), Ser16-phosphorylated phospholamban (Ser16-PLB), Thr17-phosphorylated phospholamban (Thr17-PLB),
Na+/Ca2+ exchanger (NCX1), and calsequestrin (CSQ). B) Level of SERCA2/PLB normalized to CSQ level. C) Ser16-/Total-PLB levels; D) Thr17-/Total-PLB levels. E, Protein level of the
160-kDa-NCX isoform. F, Protein levels of the 120-kDa-NCX isoform. G, NCX mRNA levels normalized to CSQ. *Pb0.05, and ***Pb0.001 vs WT, one-way ANOVA with Bonferonni post-
test. Number of mice is indicated in the bars.
1305B. Fraysse et al. / Journal of Molecular and Cellular Cardiology 52 (2012) 1299–1307in accordance with recent human data [43,44] and in mice carrying a
Myh6 mutation [45] they clearly indicate that diastolic dysfunction
can exist without LVH and is thus a primary change in HCM due to
MYBPC3mutations. Second, they indicate that diastolic dysfunction can-
not only be due to increased extracellular matrix/passive stiffness [46]
and changes in titin isoforms [47] and/or phosphorylation state
[48,49], but also due to residual actin–myosin interactions in diastole
that are the consequence of increased myoﬁlament Ca2+ sensitivity.
Thus, the data suggest that HCM is a model for diastolic heart failure
and mouse models such as the one studied here could be valuable in
studying mechanisms and treatment modalities of diastolic heart fail-
ure. Finally, the endogenous compensatory mechanism identiﬁed here
(acceleration of Ca2+ transients) could have therapeutic consequences,
because it predicts that drugs interfering with that mechanism may
have beneﬁcial or adverse effects. Thus, drugswith a desensitizing effect
onmyoﬁlament Ca2+ sensitivity (e.g. ranolazine [50]) should have ben-
eﬁcial effects, while those that increase intracellular [Na+] or [Ca2+],such as digitalis glycosides, should clearly be avoided. Studies are ongo-
ing to directly test these hypotheses.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.yjmcc.2012.03.009.Source of fundings
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Fig. 8. Transthoracic echocardiography and Doppler data. Analyses were performed in 10-week-old WT, Het and KI mice. Conventional echocardiography measurements were
obtained from B-mode. A, left ventricular mass-to-body-weight ratio (LVM/BW) and B, fractional area shortening (FAS). C, Representative pulsed-wave Doppler (PWD) recordings
of the mitral inﬂow inWT, Het and KI mice. PWD provides mitral inﬂow velocity patterns, fromwhich early (E) and late (A) diastolic velocities, as well as the E/A ratio were derived.
D, Representative tissue Doppler imaging (TDI) inWT, Het and KI mice. The E′wave corresponds to the motion of the mitral annulus during early diastolic ﬁlling of the left ventricle,
and the A′wave originates from atrial systole during late ﬁlling. E, Bars represent diastolic function parameters E/A, E′/A′ and E′E′. Data are expressed as mean±SEM with *Pb0.05,
**Pb0.01 and ***Pb001 vs WT, one-way ANOVA plus Bonferroni post-test. Number of animals is indicated in the bars.
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